Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) built from a fragment of adrenocorticotropic hormone (ACTH 4-7) joined to a stabilizing Pro-Gly-Pro tail. The ACTH portion gives it activity in the brain; the tail keeps it intact long enough to do something useful. Originally developed in Russia, where it has been used clinically for stroke and cognitive complaints, Semax has been studied for decades as a nootropic and neuroprotective compound.
What makes Semax interesting is that it appears to work on the brain's own repair and signaling machinery rather than acting like a stimulant. Research suggests it raises levels of BDNF and nerve growth factor — the molecules that keep neurons healthy and help them form new connections — and modulates the dopamine and serotonin systems involved in motivation, mood, and learning. It's typically administered intranasally, which gets it to the brain quickly and at low doses.
The research literature on Semax is unusually broad for a peptide of this size, spanning stroke recovery, learning and memory, anxiety, oxidative stress, and even copper-driven processes implicated in Alzheimer's disease.
Semax and Neurotrophin Signaling
The most studied mechanism behind Semax's cognitive effects involves BDNF — brain-derived neurotrophic factor — a protein that supports neuron survival, synapse formation, and the kind of plasticity underlying learning. A 2006 study found that intranasal Semax at modest doses (50–250 µg/kg) significantly increased BDNF levels in the basal forebrain within three hours, and identified specific, calcium-dependent binding sites for the peptide in that brain region (1). The basal forebrain is a key area for attention and memory, and the selectivity of the effect — BDNF rose there but not in the cerebellum — suggests Semax acts at targeted sites rather than broadly.
Follow-up work in models of cerebral ischemia (restricted blood flow to the brain) extended this picture. Semax selectively activated transcription of multiple neurotrophin and receptor genes — BDNF, NGF, NT-3, and the Trk family of receptors — in injured cortical tissue, with timing that suggested coordinated waves of repair signaling at 3, 24, and 72 hours after injury (2). The companion tripeptide PGP showed weaker and less selective effects, indicating the full Semax molecule is doing something its fragments can't.
This neurotrophin-boosting activity is the leading hypothesis for why Semax appears to enhance learning and protect neurons under stress.
Semax and Stroke and Brain Injury Recovery
Semax has been used clinically in Russia for acute ischemic stroke, and the preclinical work supporting that use is substantial. Beyond raising neurotrophin levels, Semax appears to modulate the brain's immune response to injury. A transcriptome analysis of cortex after focal cerebral ischemia found that Semax enhanced antigen presentation pathways, intensified interferon signaling, and shifted immunoglobulin gene expression — suggesting its neuroprotective effect involves coordinated neuroimmune crosstalk rather than a single pathway (3).
More recent work has expanded the injury model to spinal cord trauma. A 2025 study showed that Semax improved functional recovery after spinal cord injury — measured by gait analysis, motor scoring, and inclined plane tests — and reduced a form of inflammatory cell death called pyroptosis by lowering oxidative stress and stabilizing lysosomal membranes (4). Mechanistically, the work identified the µ-opioid receptor (Oprm1) as a Semax target, with downstream effects on the deubiquitinase USP18 and the regulatory protein FTO. This was the first clear demonstration that Semax's neuroprotective reach extends beyond the brain into spinal cord repair, and it adds a new receptor target to its mechanism profile.
Semax and Cognition, Mood, and Stress
Semax's reputation as a nootropic comes from its effects on the monoamine systems that govern attention, motivation, and emotional regulation. A neurochemistry study found that Semax at 0.15 mg/kg significantly increased extracellular 5-HIAA — a serotonin metabolite — in the striatum, indicating activation of serotonergic signaling, and dramatically potentiated dopamine release when paired with a stimulant challenge (5). On its own, Semax didn't flood the brain with dopamine; it appeared to prime the system to respond more strongly when activated, which fits the subjective reports of improved focus without overstimulation.
In a developmental study, Semax administered after early-life exposure to an SSRI antidepressant reduced anxiety-like behavior, improved performance in a food-motivated maze task, and normalized brain monoamine levels that had been disrupted by the early drug exposure (6). And in a learning study using avoidance conditioning, Semax counteracted the cognitive impairment caused by heavy metal toxicity (lead and molybdenum salts) at a level comparable to ascorbic acid, suggesting genuine antioxidant activity (7).
Together these findings sketch a peptide that supports cognitive performance through multiple convergent routes: neurotrophin support, monoamine modulation, and protection against oxidative damage.
Semax and Copper-Driven Neurodegeneration
A more recent line of research examines Semax in the context of Alzheimer's disease, where copper ions catalyze oxidative damage and accelerate the aggregation of amyloid-beta into the toxic clumps characteristic of the disease. Semax binds copper with high affinity, and laboratory work has shown it can strip copper away from amyloid-beta complexes, shutting down the redox cycling that generates reactive oxygen species (8). In artificial membrane models, Semax not only prevented formation of amyloid-beta:copper complexes but also inhibited fibril formation itself, with particularly strong protective effects when copper was present (9).
Follow-up cell culture work confirmed cytoprotective effects against copper-catalyzed oxidative stress in a neuronal cell line (8). This reframes part of Semax's neuroprotective profile as a metal-chelating, redox-silencing activity — a mechanism that may matter not just for Alzheimer's research but for any condition where dysregulated metal ions drive oxidative damage in the brain.